参考文献：

Adelstein DJ，Rodriguez CP，Rybicki LA，et al.2012.A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction.Invest New Drugs，30：1684-1689.

Almhanna K，Meredith KL，Hoffe SE，et al.2013.Targeting the hunan epidermal growth factor receptor 2 in esophegeal cancer.Cancer Control，20：111-116.

Bang YJ，Van Cutsem E，Feyereislova A，et al.2010.Trastuzumab in combination with chemotherapy versus chemotherapy alone fortreatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase 3，open-label，randomised controlled trial.Lancet，376：687-697.

Bendell JC，Meluch A，Peyton J，et aL 2012.A phaseⅡtrial of preoperative concurrent chemotherapy/radiation thcapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer.Clin Adv Hematol Oncol，10：430-437.(https://www.daowen.com)

Chen Y，Wu X，Bu S，et al.2012.Promising outcomes of definitive chemoradiallon and cetux imab for patients with esophageal squamous cell carcinoma.Cancer Sci，103：1979-1984.

Crosby T，Hurt CN，Falk S，et al.2013.Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer（SCOPE1）：a multicentre，phase 2/3 randomised trial.Lancet Oncol，14：627-637.

De Vita F，Orditura M，Innocente R，et al.2008.Induction primary CT with Folfox-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer（LAEC）：analysis of preliminary data from B152 trial.J Clin Onc01，26 Abstract：15524.

Dutton SJ，Ferry DR，Blazeby JM，et吐、2014.Gehtinib for oesophageal cancer progressing after chemotherapy（COG）：a phase 3，multicentre，double-blind，placebo-controlled randomised trial.Lancet OncoJ，15：894-904.